The trial aims to validate the use of circulating fetal cells in early prenatal detection of Down syndrome within the first trimester of pregnancy. Ikonisys expects this solution to be the first in a suite of non-invasive cell-based fetal tests.
Petros Tsipouras, CEO and chairman of Ikonisys, said: “With this clinical trial, we seek to prove a novel test for early non-invasive, detection of Down syndrome that eliminates the need for repeat testing and offers women the reassurance, certainty and accuracy that they need to make better, more informed decisions.”